Miyoshi, Toru <br/><br/>
Olmesartan reduces inflammatory biomarkers in patients with stable coronary artery disease undergoing percutaneous coronary intervention: results from the OLIVUS trial.  [electronic resource] 

 -  Heart and vessels  Mar 2014 
 - 178-85 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1615-2573 
<br/><br/><label>Standard No.: </label>10.1007/s00380-013-0343-0  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adiponectin--blood<br/>Aged<br/>Angina, Stable--blood<br/>Angiotensin II Type 1 Receptor Blockers--therapeutic use<br/>Anti-Inflammatory Agents--therapeutic use<br/>Biomarkers--blood<br/>C-Reactive Protein--metabolism<br/>Coronary Artery Disease--blood<br/>Coronary Vessels--drug effects<br/>Disease Progression<br/>Down-Regulation<br/>Female<br/>Humans<br/>Imidazoles--therapeutic use<br/>Inflammation Mediators--blood<br/>Japan<br/>Male<br/>Middle Aged<br/>Percutaneous Coronary Intervention<br/>Plaque, Atherosclerotic<br/>Prospective Studies<br/>Tetrazoles--therapeutic use<br/>Time Factors<br/>Treatment Outcome<br/>Ultrasonography, Interventional